BioXcel announces publication of non-clinical study on dexmedetomidine in Frontiers in Pharmacology

BioXcel Therapeutics, Inc.

Study shows dexmedetomidine potently and reversibly regulates stress-mediated behaviors.
Dexmedetomidine exhibited higher in vitro potency than clonidine, lofexidine, or guanfacine.
Mitigated responses to acute and repeated stress after both acute and repeated dosing, with no loss of effect.
No withdrawal effects; no impact on motor function or cognition vs. diazepam or scopolamine.
Results support BXCL-501's potential for stress-related disorders beyond acute agitation.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.